Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 by Wysham, Carol H. & Kirkman, M. Sue
COMMENTS AND
RESPONSES
Response to
Comment on:
American Diabetes
Association.
Standards of Medical
Care in Diabetes—
2011. Diabetes Care
2011;34(Suppl. 1):
S11–S61
W
e appreciate the opportunity to
respond to the letter of Basevi
e ta l .( 1 ) .T h en e wr e c o m m e n -
dations by the American Diabetes Asso-
ciation (ADA) for gestational diabetes
mellitus (GDM) screening and diagnosis
arelevelBrecommendations(“supportive
evidence from well-conducted cohort
studies”). As described in our Standards
of Medical Care (2), the ADA adopted the
consensus recommendations of an in-
ternational group convened by the In-
ternational Association of Diabetes and
Pregnancy Study Groups (IADPSG), on
the basis of the group’s extensive review
of published and unpublished data from
themultinationalHyperglycemiaandAd-
verse Pregnancy Outcome(HAPO)study.
The cut points chosen represent those
that confer an odds ratio of 1.75, com-
paredwiththe meanvalues, fora number
of prespeciﬁed adverse pregnancy out-
comes (3).
The recommendation for universal
GDM screening is not a major change.
Prior ADA recommendations were to
screen all but very low-risk women (in
theU.S.,averysmallminorityofpregnant
women), either with a one- or two-step
protocol.Thefastingplasmaglucose(FPG)
cut point is only slightly lower than
the prior recommendation (95 mg/dL
[5.3 mmol/L]). Using an FPG cut point of
126 mg/dL (7 mmol/L) to diagnose GDM
isnotthestandardofcareinmostsystems.
In fact, in the HAPO study, women with
FPG .105 mg/dL (5.8 mmol/L) were un-
blinded and not included in the untreated
observational cohort for ethical reasons.
The main critique of the recommen-
d a t i o n si st h a tm o r ew o m e nw i l lb e
diagnosed with GDM because only one
abnormaloralglucosetolerancetestvalue
is required. The IADPSG group’s analyses
showed that valuesatany ofthethreeoral
glucose tolerance time points were infor-
mativeofrisk.Bydeﬁnition,womeniden-
tiﬁedwiththenewcriteriawhowouldnot
havebeen identiﬁedbypriorADAcriteria
will have milder GDM. We disagree that
treatment of GDM has limited beneﬁtb e -
yond reduction in shoulder dystocia. The
U.S.study(withdiagnosticcriteriasimilar
to the IADPSG criteria) showed sig-
niﬁcant reductions in rates of primary
cesarean section and in preeclampsia
and gestational hypertension with identi-
ﬁcation and treatment of mild GDM (4).
Both the U.S. and Australian studies
showed signiﬁcant reductions in macro-
somia (a known risk factor for futureobe-
sity and diabetes) (4,5). The latter study
showed improved postpartum measures
of maternal quality of life and lower rates
of depression (5). In the U.S. study, 93%
oftreatedwomenweremanagedwithlife-
style therapy alone. It is likely that the
morehyperglycemicwomenrequiringin-
sulin treatment would have been diag-
nosed by prior criteria.
For years GDM has been deﬁned
differently throughout the world—a
patchwork that stymies epidemiological
analyses and harmonization of clinical re-
search and care. Prior diagnostic criteria
were notbased onevidencefor pregnancy-
relatedoutcomes.TheIADPSGrecommen-
dationsareahighlyrationalwaytoidentify
women athigher risk ofadversepregnancy
outcomes—outcomes that can be reduced
primarily with lifestyle interventions. The
ADA therefore joined numerous diabetes
and obstetrical organizations worldwide
in adopting these recommendations.
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